“…To overcome these drawbacks, several plasmonic nanostructured-based (“nanoplasmonic”), solid-state serology assays have been developed for COVID-19 antibody detection. ,,,− Nanoplasmonic assays utilize the unique localized surface plasmon resonance (LSPR) property of noble metal nanostructures that originates due to collective oscillation of free electrons upon light irradiation. , Furthermore, with an appropriate choice of nanostructures, along with the suitable surface chemistry anchoring receptor molecules, highly sensitive and specific nanoplasmonic biosensors can be fabricated for protein assays in human biofluids. − In the context of COVID-19 serology antibody assays, current plasmonic-based antibody assays lack specificity. , Moreover, these assays use an anti-human antibody (anti-IgG, anti-IgM, and anti-IgA) as receptor molecules in the biosensor construct to detect SARS-CoV-2 antibodies (IgG, IgM, and IgA). ,,− However, these anti-human antibodies (anti-IgG, anti-IgM, and anti-IgA) are known to be abundant in blood and may compete with target SARS-CoV-2 antibodies for binding with anti-human antibody receptors, leading to non-SARS-CoV-2 antibody specific receptors. ,,, In order to develop a highly specific serology antibody assay for COVID-19, one must select a SARS-CoV-2 antibody specific receptor.…”